Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.

Gabriel EtienneStéphanie DulucqFrançoise HuguetAnna SchmittAxelle LascauxSandrine HayetteMarie-Pierre FortPierre SujobertFontanet BijouStéphane MorissetSuzanne TavitianAudrey BidetBeatrice TurcqFanny RobbesynClaudine CholletFrancis BellocFrançoise DurrieuFrançois-Xavier MahonFranck E Nicolini

Published in: Cancer medicine (2019)

Our results suggest that early mutation detection together with accessibility to 2nd and 3rd generation TKIs have reversed the worst outcome associated with BCR-ABL KD mutations whatever the mutation subgroup in CP-CML patients.

Keyphrases

chronic myeloid leukemia
end stage renal disease
newly diagnosed
ejection fraction
risk factors
peritoneal dialysis
randomized controlled trial
patient reported outcomes
loop mediated isothermal amplification
open label
patient reported
real time pcr
quantum dots